New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe

Ilias Houda*, Chris Dickhoff, Carin A. Uyl-de Groot, Noemi Reguart, Mariano Provencio, Antonin Levy, Rafal Dziadziuszko, Cecilia Pompili, Massimo Di Maio, Michael Thomas, Alessandro Brunelli, Sanjay Popat, Suresh Senan, Idris Bahce

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

6 Citations (Scopus)
10 Downloads (Pure)

Abstract

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) compares and contrasts approaches taken by the European Medicines Agency (EMA) for drug approval to that taken by the United States Food and Drug Administration (FDA), and (iii) evaluates the differences in access to emerging treatments from an availability perspective across European countries.

Original languageEnglish
Article number100840
JournalThe Lancet Regional Health - Europe
Volume38
DOIs
Publication statusPublished - Mar 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s)

Fingerprint

Dive into the research topics of 'New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe'. Together they form a unique fingerprint.

Cite this